Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478405 | 0.95 | MAPK14 (0.90) | MAPK14SMN1; SMN2LMNAL3MBTL1MAPT | |
| SCHEMBL4490267 | 0.94 | MAPK14 (0.77) | MAPK14SMN1; SMN2LMNAL3MBTL1NCOA3 | |
| SCHEMBL4470415 | 0.92 | MAPK14 (1.00) | MAPK14SMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL4466494 | 0.90 | MAPK14 (1.00) | MAPK14SMN1; SMN2MAPTTHRBALDH1A1 | |
| SCHEMBL4474779 | 0.90 | MAPK14 (0.90) | MAPK14SMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL4379163 | 0.89 | MAPK14 (1.00) | MAPK14SMN1; SMN2 | |
| SCHEMBL4468370 | 0.89 | MAPK14 (0.87) | MAPK14SMN1; SMN2LMNAMEN1ALDH1A1 | |
| SCHEMBL4470817 | 0.89 | MAPK14 (0.87) | MAPK14SMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL4469536 | 0.89 | MAPK14 (0.87) | MAPK14SMN1; SMN2LMNAMEN1ALDH1A1 | |
| SCHEMBL4478817 | 0.89 | MAPK14 (0.82) | MAPK14SMN1; SMN2LMNAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | claimed |
| US-20060211694-A1 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT (US) | 2006-09-21 | — | — | US | claimed |
| CN-1646125-A | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2005-07-27 | — | — | CN | claimed |
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| CN-101531631-B | Substituted pyridinones as modulators of p38 map kinase | PHARMACIA CORP | 2011-09-28 | — | — | CN | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| CN-101531631-A | Substituted pyridinones as modulators of p38 map kinase | PHARMACIA CORP (US) | 2009-09-16 | — | — | CN | disclosed |
| CN-100486576-C | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2009-05-13 | — | — | CN | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| CN-1646125-A | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2005-07-27 | — | — | CN | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MAPK14 41/4885SMN1; SMN2 1433/4885LMNA 1815/4885 |
| US-20060211694-A1 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | LTB4R2, LTB4R, MAPK1 | MAPK14 79/4885SMN1; SMN2 4119/4885LMNA 3852/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 53/4885SMN1; SMN2 1419/4885LMNA 1884/4885 |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 46/4885SMN1; SMN2 1990/4885LMNA 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.